Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
stocks
Investors overlooking ASX share’s potential
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,735.40 | 83.10 | -0.94% |
| CAC 40 | 7,987.49 | 34.94 | 0.44% |
| DAX 40 | 24,307.92 | 357.35 | 1.49% |
| Dow JONES (US) | 49,614.64 | 88.47 | 0.18% |
| FTSE 100 | 10,323.75 | 128.38 | 1.26% |
| HKSE | 25,675.18 | 287.55 | -1.11% |
| NASDAQ | 26,046.02 | 179.13 | -0.68% |
| Nikkei 225 | 60,815.95 | 593.34 | -0.97% |
| NZX 50 Index | 12,762.92 | 202.09 | -1.56% |
| S&P 500 | 7,391.87 | 16.63 | -0.22% |
| S&P/ASX 200 | 8,505.30 | 72.60 | -0.85% |
| SSE Composite Index | 4,131.53 | 3.86 | -0.09% |